Platelet surface receptors and blood components

Platelet surface receptors and blood components is a broad classification encompassing the cellular and molecular constituents of blood that mediate hemostasis, thrombosis, and inflammatory responses [1, 2]. This category includes the primary cellular elements—erythrocytes (red blood cells), leukocytes (white blood cells), and thrombocytes (platelets)—as well as the plasma proteins and surface receptors that coordinate their physiological functions [2]. Key platelet surface receptors include the integrin alpha-IIb/beta-3 (GPIIb/IIIa) complex, which is the final common pathway for platelet aggregation, and the GPIb-IX-V complex, which initiates adhesion by binding to von Willebrand factor [3, 4]. Other critical receptors include the purinergic P2Y12 and P2Y1 receptors, which respond to ADP, and protease-activated receptors (PAR-1 and PAR-4), which are activated by thrombin [3, 5]. These components are the primary targets for a wide range of therapeutic agents, including antiplatelet drugs (e.g., aspirin, clopidogrel) and anticoagulants (e.g., heparin, warfarin), which are essential in managing cardiovascular diseases such as myocardial infarction and stroke [4, 5]. Dysregulation of these receptors or an imbalance in blood components can lead to pathological conditions ranging from arterial thrombosis to severe bleeding disorders [2, 3]. Their involvement in cardiovascular disease and inflammation makes them central to modern pharmacological research [2, 5].

Other names

Platelet receptorsBlood constituentsHemostatic componentsBlood cell surface receptors

Inhibition of platelet aggregation through various pathways, including the antagonism of P2Y12 receptors, blockade of the GPIIb/IIIa integrin complex, inhibition of cyclooxygenase-1 (COX-1) to prevent thromboxane A2 synthesis, and antagonism of protease-activated receptors (PAR-1). Additionally, modulation of the coagulation cascade via inhibition of clotting factors or their synthesis.